Karin Jirström
Professor
Research Interests
Explore related searches
Contact this professor
About
Professor Karin Jirström is a faculty member at Lund University in Sweden. Her research encompasses various aspects of oncology, including tumor evolution and response in liver cancer, the clinical significance of insulin-like growth factor binding proteins in breast cancer, and the role of programmed death-ligand 1 in colorectal cancer prognosis. Additionally, she investigates the tumor microenvironment in triple-negative breast cancer and the impact of specific markers in gastric and esophageal adenocarcinomas.
Articles (22)
The Vitamin D Receptor as a Prognostic Marker in Breast Cancer—A Cohort Study
Previous research has indicated an association between the presence of the vitamin D receptor (VDR) in breast cancer tissue and a favorable prognosis. This study aimed to further evaluate the prognostic potential of VDR located in the nuclear membrane or nucleus (liganded). The VDR protein levels were analyzed using immunohistochemistry in tumor samples from 878 breast cancer patients from Lund, Sweden, included in the Breast Cancer and Blood Study (BCBlood) from October 2002 to June 2012. The follow-up for breast cancer events and overall survival was recorded until 30 June 2019. Univariable and multivariable survival analyses were conducted, both with complete case data and with missing data imputed using multiple imputation by chained equations (MICE). Tumor-specific positive nuclear membrane VDR(num) staining was associated with favorable tumor characteristics and a longer breast cancer free interval (BCFI; HR: 0.64; 95% CI: 0.44–0.95) and overall survival (OS; HR: 0.52; 95% CI: 0.34–0.78). Further analyses indicated that VDRnum status also was predictive of overall survival when investigated in relation to ER status. There were significant interactions between VDR and invasive tumor size (Pinteraction = 0.047), as well as mode of detection (Pinteraction = 0.049). VDRnum was associated with a longer BCFI in patients with larger tumors (HR: 0.36; 95% CI: 0.14–0.93) or clinically detected tumors (HR: 0.28; 95% CI: 0.09–0.83), while no association was found for smaller tumors and screening-detected tumors. Further studies are suggested to confirm our results and to evaluate whether VDR should and could be used as a prognostic and targetable marker in breast cancer diagnostics.
Year:
2024
Collaborators (23)
Johan Vallon-Christersson
Lund University
Aidan Meade
Technological University Dublin
Hans Brunnström
Lund University
Alfonso Martín-Bernabé
Karolinska Institutet
Miklos Gulyas
MD, PhD, associate professor, senior consultant pathologist
Uppsala Universitet Medicinska fakulteten
Johan Staaf
Lund University
Signe Borgquist
Aarhus University
Konstantinos Papadakos
Lund University
Jenny Karlsson
Lund University
Subhayan Chattopadhyay
Lund University
Helena Jernström
Lund University
Mihaela Asp
Lund University
Karin Leandersson
Lund University
Johan Isaksson
Head of Department
-
Thi Nguyet Que Nguyen
Technological University Dublin
Jutta Huvila
University of Turku
Carina Strell
Karolinska Institutet
Caroline Bergenfelz
Lund University
Anna Blom
Umeå Universitet Medicinska fakulteten
Natalie Andersson
Lund University
Christopher Godina
Lund University
Anders Valind
Lund University
Artur Mezheyeuski
Uppsala University

How do I reach out?
Sign in for free to see their profile details and contact information.